Human LIF Antibody, R&D Systems™

LIF

Monoclonal

Unconjugated

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative

LIF

E. coli-derived recombinant human LIF

500 μg

Primary

Detects human LIF in ELISAs and Western blots. In sandwich immunoassays, no significant cross-reactivity or interference with recombinant human (rh) IL-1 alpha , rhIL-1 beta , rhIL-2, rhIL-3, rhIL-4, rhIL-6, rhIL-7, rhIL-8, rhG-CSF, rhGM-CSF, rhOSM, rhTGF-beta 1, rhTNF-alpha , rhTNF-beta , recombinant mouse (rm) IL-1 beta , rmIL-3, rmIL-4, rmIL-5, rmIL-6, rmIL-7, rmGM-CSF, bovine (b) FGF acidic, bFGF basic, human (h) PDGF, porcine (p) PDGF, hTGF-beta 1, pTGF-beta 1.2, or pTGF-beta 2 is observed.

Human

Ascites

Immunohistochemistry, Neutralization, ELISA

9824

Immunohistochemistry 8-25 ug/mL, Neutralization 0.06-0.2 ug/mL, ELISA Capture (Matched Antibody Pair) 2-8 ug/mL

CDF, D factor, DIA, differentiation inhibitory activity, differentiation stimulating factor, Differentiation-stimulating factor, Emfilermin, HILDA, HILDAcholinergic differentiation factor, leukemia inhibitory factor, leukemia inhibitory factor (cholinergic differentiation factor), Melanoma-derived LPL inhibitor, MLPLI

Mouse

Protein A or G purified from ascites

RUO

3976

Reconstitute at 0.5 mg/mL in sterile PBS.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.

IgG2b